Development of a first medical device in a therapeutic class to be used for the treatment of a natural breakthrough in the patients suffering from a fromeye village (Q78631): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item: Fixing rounding issue)
(‎Removed claim: summary (P836): Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).The aim of the project is to develop a new therapeutic medical device, the use of which will be the first in the world to be used, in the form of a targeted...)
Property / summary
Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).The aim of the project is to develop a new therapeutic medical device, the use of which will be the first in the world to be used, in the form of a targeted therapy, to be used for patients suffering from a frost-free town in the course of a small town.The product, in the form of a biomolecular filter containing avian influenza, will be used during a targeted apheresis procedure, an improved version of the known and used medical procedure.The alleged popup (MG) is a rare self-immune disease in the self-immune part of the neuromuscular joint, with muscular fatigue.As in the USA, the prevalence of prevalence (prevalence) for a small town in the European Union is 20 per 100 000 inhabitants, so it is rare for rare diseases.In 70 % of patients, at least once in the course of an illness, there is a sudden and serious deterioration of the so-called “small local crisis”, which is the most likely to cause severe respiratory distress.The treatment of plasma is a standard procedure in the course of the crisis, but it is highly non-specific and, moreover, with significant spill-over effects.Therefore, the introduction of a specific treatment on the market for these patients is likely to improve their quality of life and reduce mortality by addressing one of the many unmet medical needs.High Unmet Medical Need) within rare diseases.The project will therefore be part of a global strategy to develop new therapeutic solutions, not only for conditions affecting a significant part of the population, but also for poorly perceived, often just as, serious illnesses and illnesses. (English)
 
Property / summary: Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).The aim of the project is to develop a new therapeutic medical device, the use of which will be the first in the world to be used, in the form of a targeted therapy, to be used for patients suffering from a frost-free town in the course of a small town.The product, in the form of a biomolecular filter containing avian influenza, will be used during a targeted apheresis procedure, an improved version of the known and used medical procedure.The alleged popup (MG) is a rare self-immune disease in the self-immune part of the neuromuscular joint, with muscular fatigue.As in the USA, the prevalence of prevalence (prevalence) for a small town in the European Union is 20 per 100 000 inhabitants, so it is rare for rare diseases.In 70 % of patients, at least once in the course of an illness, there is a sudden and serious deterioration of the so-called “small local crisis”, which is the most likely to cause severe respiratory distress.The treatment of plasma is a standard procedure in the course of the crisis, but it is highly non-specific and, moreover, with significant spill-over effects.Therefore, the introduction of a specific treatment on the market for these patients is likely to improve their quality of life and reduce mortality by addressing one of the many unmet medical needs.High Unmet Medical Need) within rare diseases.The project will therefore be part of a global strategy to develop new therapeutic solutions, not only for conditions affecting a significant part of the population, but also for poorly perceived, often just as, serious illnesses and illnesses. (English) / rank
Normal rank
 

Revision as of 14:37, 14 October 2020

Project in Poland financed by DG Regio
Language Label Description Also known as
English
Development of a first medical device in a therapeutic class to be used for the treatment of a natural breakthrough in the patients suffering from a fromeye village
Project in Poland financed by DG Regio

    Statements

    country
    Poland
    0 references
    EU contribution
    10,775,212.49 zloty
    0 references
    2,586,051.00 Euro
    exchange rate to Euro
    0.24 Euro
    point in time
    13 January 2020
    0 references
    budget
    14,733,265.56 zloty
    0 references
    3,535,983.73 Euro
    exchange rate to Euro
    0.24 Euro
    point in time
    13 January 2020
    0 references
    co-financing rate
    73.14 percent
    0 references
    start time
    1 May 2019
    0 references
    end time
    31 December 2023
    0 references
    beneficiary name (string)
    PURE BIOLOGICS SPÓŁKA AKCYJNA
    0 references
    beneficiary
    Q2509459
    0 references
    coordinate location

    51°7'34.7"N, 16°58'41.5"E
    0 references
    summary
    Numer_referencyjny_programu_pomocowego: SA.41471(2015/X)Przeznaczenie_pomocy_publicznej: art. 25 rozporządzenia KE nr 651/2014 z dnia 17 czerwca 2014 r. uznające niektóre rodzaje pomocy za zgodne z rynkiem wewnętrznym w stosowaniu art. 107 i 108 Traktatu (Dz. Urz. UE L 187/1 z 26.06.2014). Celem projektu jest opracowanie nowego terapeutycznego urządzenia medycznego, którego zastosowaniem będzie pierwsza na świecie celowana terapia przeznaczona dla pacjentów cierpiących na miastenię rzekomoporaźną, znajdujących się w trakcie przełomu miastenicznego. Produkt, w postaci biomolekularnego filtra zawierającego aptamery, stosowany będzie podczas zabiegu ukierunkowanej aferezy - ulepszonej wersji znanej i stosowanej procedury medycznej. Miastenia rzekomoporaźna (MG) jest rzadką chorobą autoimmunologiczną części postsynaptycznej złącza nerwowo-mięśniowego, objawiającą się męczliwością mięśni. Współczynnik chorobowości (ang. prevalence) dla miastenii rzekomoporaźnej w Unii Europejskiej, podobnie jak w USA, wynosi 20 na 100 000 mieszkańców, zatem choroba ta zaliczana jest do chorób rzadkich. U 70% pacjentów, co najmniej raz w ciągu przebiegu choroby, dochodzi do nagłego i ciężkiego pogorszenia, tzw. kryzysu miastenicznego, prowadzącego najczęściej do ciężkiej niewydolności oddechowej. Terapeutyczna plazmafereza (wymiana osocza) jest standardowym schematem postępowania w trakcie kryzysu, ale jest to terapia wysoce niespecyficzna i ponadto obarczona znaczącymi skutkami ubocznymi. Wprowadzenie zatem na rynek specyficznej terapii przeznaczonej dla tych pacjentów ma szansę poprawić ich jakość życia i zmniejszyć śmiertelność, adresując jedną z wielu niezaspokojonych potrzeb medycznych (ang. High Unmet Medical Need) w obrębie chorób rzadkich. Tym samym projekt wpisuje się w ogólnoświatową strategię rozwijania nowych rozwiązań terapeutycznych nie tylko dla schorzeń dotykających znaczącej części populacji, ale również słabo dostrzeganych choć często równie ciężkich i groźnych chorób (Polish)
    0 references

    Identifiers

    Polish Kohesio ID
    POIR.01.01.01-00-1166/18
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q78631&oldid=6348020"